QNCX Quince Therapeutics Net earnings per share for the last 12 months

Quince Therapeutics (QNCX) is developing a unique drug delivery method via erythrocytes, while management focuses on M&A transactions and investor protection. The fundamental EPS TTM metric helps assess the issuer's financial stability, with -124.48 representing the latest level. To develop drugs for bone pathologies, Quince Therapeutics is implementing AI algorithms and partially automating laboratory synthesis.
Analytical breakdowns and data insights for company Quince Therapeutics (QNCX)

Conservative capital demands maximum transparency in profit distribution among shareholders. This indicator measures the portion of net income attributable to a single common share over a rolling year, excluding the impact of one-time factors. For Quince Therapeutics (QNCX), which is developing innovative treatments for rare pathologies, this metric reflects the efficiency of capitalizing scientific achievements. Analyzing the 12-month rolling earnings per share history allows for a comparison of actual returns against market expectations.